Stocks of Esperion Therapeutics Inc (NASDAQ:ESPR) traded higher last session on Wall Street, up 6.67% to $1.12.
ESPR stock price is now 9.78% away from the 50-day moving average and -37.27% away from the 200-day moving average. The market capitalization of the company currently stands at $221.98M.
With the price target of $4, Goldman recently initiated with Neutral rating for Esperion Therapeutics Inc (NASDAQ: ESPR). On December 17, 2024, Cantor Fitzgerald recently initiated its ‘Overweight’ rating on the stock quoting a target price of $8, while ‘BofA Securities’ rates the stock as ‘Underperform’
In other news, Warren Eric, Chief Commercial Officer sold 108 shares of the company’s stock on Apr 17 ’25. The stock was sold for $106 at an average price of $0.98. Upon completion of the transaction, the Chief Commercial Officer now directly owns 370,218 shares in the company, valued at $0.41 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 17 ’25, Chief Financial Officer Halladay Benjamin sold 8 shares of the business’s stock. A total of $8 was realized by selling the stock at an average price of $0.96. This leaves the insider owning 481,702 shares of the company worth $0.54 million. A total of 1.76% of the company’s stock is owned by insiders.
During the past 12 months, Esperion Therapeutics Inc has had a low of $0.69 and a high of $3.94. The fifty day moving average price for ESPR is $1.02 and a two-hundred day moving average price translates $1.78525 for the stock.
The latest earnings results from Esperion Therapeutics Inc (NASDAQ: ESPR) was released for 2025-03-31.
